DeSantis, C. E. et al. Breast cancer statistics, 2019. CA Cancer J. Clin. 69, 438–451 (2019).

Article  PubMed  Google Scholar 

Giaquinto, A. N. et al. Breast cancer statistics, 2022. CA Cancer J. Clin. 72, 524–541 (2022).

Article  PubMed  Google Scholar 

Badve, S. S. & Gökmen-Polar, Y. Ductal carcinoma in situ of breast: update 2019. Pathology 51, 563–569 (2019).

Article  PubMed  Google Scholar 

Shaaban, A. M. et al. Pathological features of 11,337 patients with primary ductal carcinoma in situ (DCIS) and subsequent events: results from the UK Sloane Project. Br. J. Cancer 124, 1009–1017 (2021).

Article  CAS  PubMed  Google Scholar 

Groen, E. J. et al. Prognostic value of histopathological DCIS features in a large-scale international interrater reliability study. Breast Cancer Res. Treat. 183, 759–770 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Maxwell, A. J. et al. Unresected screen-detected ductal carcinoma in situ: outcomes of 311 women in the Forget-Me-Not 2 study. Breast Edinb. Scotl. 61, 145–155 (2022).

Article  Google Scholar 

Sanders, M. E., Schuyler, P. A., Dupont, W. D. & Page, D. L. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer 103, 2481–2484 (2005).

Article  PubMed  Google Scholar 

Collins, L. C. et al. Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses’ Health Study. Cancer 103, 1778–1784 (2005).

Article  PubMed  Google Scholar 

Page, D. L., Dupont, W. D., Rogers, L. W. & Landenberger, M. Intraductal carcinoma of the breast: follow-up after biopsy only. Cancer 49, 751–758 (1982).

Article  CAS  PubMed  Google Scholar 

Betsill, W. L., Rosen, P. P., Lieberman, P. H. & Robbins, G. F. Intraductal carcinoma: long-term follow-up after treatment by biopsy alone. JAMA 239, 1863–1867 (1978).

Article  PubMed  Google Scholar 

Fu, F., Gilmore, R. C. & Jacobs, L. K. Ductal carcinoma in situ. Surg. Clin. North Am. 98, 725–745 (2018).

Article  PubMed  Google Scholar 

Nguyen, D. L., Greenwood, H. I., Rahbar, H. & Grimm, L. J. Evolving treatment paradigms for low-risk ductal carcinoma in situ: imaging needs. AJR Am. J. Roentgenol. https://doi.org/10.2214/AJR.23.30503 (2023).

DeSantis, C. E., Ma, J., Goding Sauer, A., Newman, L. A. & Jemal, A. Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J. Clin. 67, 439–448 (2017).

Article  PubMed  Google Scholar 

Sanati, S. Morphologic and molecular features of breast ductal carcinoma in situ. Am. J. Pathol. 189, 946–955 (2019).

Article  CAS  PubMed  Google Scholar 

Grimm, L. J., Rahbar, H., Abdelmalak, M., Hall, A. H. & Ryser, M. D. Ductal carcinoma in situ: state-of-the-art review. Radiology 302, 246–255 (2022).

Article  PubMed  Google Scholar 

Gajdos, C. et al. Mammographic appearance of nonpalpable breast cancer reflects pathologic characteristics. Ann. Surg. 235, 246–251 (2002).

Article  PubMed  PubMed Central  Google Scholar 

Farante, G. et al. Advances and controversies in management of breast ductal carcinoma in situ (DCIS). Eur. J. Surg. Oncol. 48, 736–741 (2022).

Article  PubMed  Google Scholar 

Yu, K.-D. et al. Different distribution of breast cancer subtypes in breast ductal carcinoma in situ (DCIS), DCIS with microinvasion, and DCIS with invasion component. Ann. Surg. Oncol. 18, 1342–1348 (2011).

Article  PubMed  Google Scholar 

Thorat, M. A. et al. Prognostic and predictive value of HER2 expression in ductal carcinoma in situ: results from the UK/ANZ DCIS randomized trial. Clin. Cancer Res. 27, 5317–5324 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Latta, E. K., Tjan, S., Parkes, R. K. & O’Malley, F. P. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast. Mod. Pathol. 15, 1318–1325 (2002).

Article  CAS  PubMed  Google Scholar 

Sadeghalvad, M., Mohammadi-Motlagh, H.-R. & Rezaei, N. Immune microenvironment in different molecular subtypes of ductal breast carcinoma. Breast Cancer Res. Treat. 185, 261–279 (2021).

Article  CAS  PubMed  Google Scholar 

Virnig, B. A., Tuttle, T. M., Shamliyan, T. & Kane, R. L. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. JNCI J. Natl Cancer Inst. 102, 170–178 (2010).

Article  PubMed  Google Scholar 

Worni, M. et al. Trends in treatment patterns and outcomes for ductal carcinoma in situ. J. Natl Cancer Inst. 107, djv263 (2015).

Article  PubMed  PubMed Central  Google Scholar 

Van Bockstal, M. R., Agahozo, M. C., Koppert, L. B. & van Deurzen, C. H. M. A retrospective alternative for active surveillance trials for ductal carcinoma in situ of the breast. Int. J. Cancer 146, 1189–1197 (2020).

Article  PubMed  Google Scholar 

Wellings, S. R. & Jensen, H. M. On the origin and progression of ductal carcinoma in the human breast. J. Natl Cancer Inst. 50, 1111–1118 (1973).

Article  CAS  PubMed  Google Scholar 

Doebar, S. C. et al. Gene expression differences between ductal carcinoma in situ with and without progression to invasive breast cancer. Am. J. Pathol. 187, 1648–1655 (2017).

Article  CAS  PubMed  Google Scholar 

Collins, L. C. et al. Risk factors for non-invasive and invasive local recurrence in patients with ductal carcinoma in situ. Breast Cancer Res. Treat. 139, 453–460 (2013).

Article  PubMed  PubMed Central  Google Scholar 

Wang, S.-Y., Shamliyan, T., Virnig, B. A. & Kane, R. Tumor characteristics as predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis. Breast Cancer Res. Treat. 127, 1–14 (2011).

Article  CAS  PubMed  Google Scholar 

Atakpa, E. C., Thorat, M. A., Cuzick, J. & Brentnall, A. R. Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review. Cochrane Database Syst. Rev. 10, CD013091 (2021).

PubMed  Google Scholar 

Knowlton, C. A., Jimenez, R. B. & Moran, M. S. DCIS: risk assessment in the molecular era. Semin. Radiat. Oncol. 32, 189–197 (2022).

Article  PubMed  Google Scholar 

Nolan, E., Lindeman, G. J. & Visvader, J. E. Deciphering breast cancer: from biology to the clinic. Cell 186, 1708–1728 (2023).

Article  CAS  PubMed  Google Scholar 

Hua, H., Zhang, H., Kong, Q. & Jiang, Y. Mechanisms for estrogen receptor expression in human cancer. Exp. Hematol. Oncol. 7, 24 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Clusan, L., Le Goff, P., Flouriot, G. & Pakdel, F. A closer look at estrogen receptor mutations in breast cancer and their implications for estrogen and antiestrogen responses. Int. J. Mol. Sci. 22, 756 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Swain, S. M., Shastry, M. & Hamilton, E. Targeting HER2-positive breast cancer: advances and future directions. Nat. Rev. Drug Discov. 22, 101–126 (2023).

Article  CAS  PubMed  Google Scholar 

Yang, Y. et al. HER2-driven breast tumorigenesis relies upon interactions of the estrogen receptor with coactivator MED1. Cancer Res. 78, 422–435 (2018).

Article  CAS  PubMed  Google Scholar 

Hoxhaj, G. & Manning, B. D. The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. Nat. Rev. Cancer 20, 74–88 (2020).

Article  CAS  PubMed  Google Scholar 

Butti, R. et al. Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges. Mol. Cancer 17, 34 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Riggio, A. I., Varley, K. E. & Welm, A. L. The lingering mysteries of metastatic recurrence in breast cancer. Br. J. Cancer 124, 13–26 (2021).

Article  PubMed  Google Scholar 

Lin, D. et al. Circulating tumor cells: biology and clinical significance. Signal Transduct. Target. Ther. 6, 404 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Buyuk, B., Jin, S. & Ye, K. Epithelial-to-mesenchymal transition signaling pathways responsible for breast cancer metastasis. Cell. Mol. Bioeng. 15, 1–13 (2022).

Article  CAS  PubMed